Oral edaravone ameliorates myocardial fibrosis in diabetic rats by TGF-beta1/Smad signaling pathway
Myocardial fibrosis, characterized by increased reactive oxygen species (ROS), is a key pathological feature of diabetic cardiomyopathy (DCM). Although oral edaravone (EDA) shows therapeutic potential in ameliorating myocardial fibrosis in DCM, the precise mechanisms remain unclear.